Tracers / [90Y]Y-DOTA-Phe1-Tyr3-octreotide
[90Y]Y-DOTA-Phe1-Tyr3-octreotide
Also written as [Y-90]DOTA-Phe1-Tyr3-octreotide; Y-90-DOTA-Phe1-Tyr3-Octreotide
- Radionuclide
- Y-90 t½ 3843.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- Phase I/II
- Syntheses indexed
- 7
What it is
- Compound class
- Radiolabeled somatostatin analogue peptide
- Target / mechanism
- Somatostatin receptors (SSTR) PMID 19635228
- Clinical application
- Metastatic/progressive neuroendocrine (carcinoid) tumors PMID 19635228
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| — | — | — | — | — | — | 18349800 2008 Nucl Med Commun |
| — | — | — | — | — | — | 15068609 2004 Cancer Biother Radiopharm |
| — | — | — | — | — | DOTA-D-Phe1-Try3-octreotide | 12658726 2002 Biopolymers |
| — | — | — | — | — | — | 11835112 2001 Swiss Med Wkly |
| — | — | — | — | — | — | 11403179 2001 Nucl Med Commun |
| — | — | — | — | — | DOTA-[D-Phe1-Tyr3]-octreotide | 11357492 2001 Eur J Nucl Med |
| — | — | — | — | — | DOTA-D-Phe1-Tyr3-Octreotide | 10850334 1999 Cancer Biother Radiopharm |
Need this precursor?We can point you to suppliers for [90Y]Y-DOTA-Phe1-Tyr3-octreotide, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty.